5 January 2024 - The Department of Health has published a revised agenda (version 3) for the March 2024 PBAC meeting.

The revised agenda includes a number of new (re)submissions:

• Cabozantinib maleate (Cabometyx) - new indication
• Edarvarone (Radicava) - new medicine
• Icosapent ethyl (Vazkepa) - new medicine
• Rimegapant sulphate (Nurtec ODT) - new medicine
• Risperidone (Okedi) - new formulation
• Tiotropium bromoide monohydrate (Tiotropium Lupin) - new formulation
• Trastuzumab deruxtecan (Enhertu) - new indication

Read PBAC agenda